Top 50 Biotechnology Startup Investors in Australia (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Uniseed
VC Fund
|
27 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Manufacturing | $404k–$22M |
|
Uniseed Ventures
VC Fund
|
21 | Australia, United States, United Kingdom | Series A, Seed | Biotechnology, Health Care, Manufacturing | $381k–$16M |
|
Brandon Capital
VC Fund
|
17 | Australia, United Kingdom, United States | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $673k–$120M |
|
Medical Research Commercialisation Fund (MRCF)
VC Fund
|
11 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $1.3M–$16M |
|
Main Sequence Ventures
VC Fund
|
9 | Australia, United States, Philippines | Seed, Series A, Series B | Software, Artificial Intelligence, Manufacturing | $1M–$73M |
|
Stoic VC
VC Fund
|
9 | Australia, United States, United Kingdom | Seed, Series A | Biotechnology, Medical, Health Care | $600k–$16M |
|
Melbourne Angels
VC Fund
|
6 | Australia, United States, New Zealand | Angel, Seed | Biotechnology, Information Technology, Internet | $34k–$1.3M |
|
Artesian VC
VC Fund
|
5 | Australia, United States, Hong Kong | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Health Care | $40k–$15M |
|
Horizons Ventures
VC Fund
|
5 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Software, Artificial Intelligence | $1M–$110M |
|
OneVentures
VC Fund
|
5 | Australia, United States, Israel | Series A, Debt Financing | Software, Health Care, Biotechnology | $1M–$20M |
|
Sydney Angels
VC Fund
|
5 | Australia, United States | Seed, Angel, Series A | Software, SaaS, Health Care | $120k–$4.8M |
|
Brisbane Angels
VC Fund
|
4 | Australia, United States, New Zealand | Seed, Angel, Pre-Seed | Software, Biotechnology, Machine Learning | $120k–$1.3M |
|
IP Group Australia
VC Fund
|
3 | Australia, New Zealand | Seed, Pre-Seed, Series A | Biotechnology, Manufacturing, Renewable Energy | $811k–$29M |
|
Clean Energy Finance Corporation
VC Fund
|
3 | Australia, United States, Spain | Debt Financing, Series B | Energy, Renewable Energy, Real Estate | $5M–$333M |
|
GBS Ventures
VC Fund
|
3 | United States, Australia, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.2M–$55M |
|
Breakthrough Victoria
VC Fund
|
3 | Australia, United States, Philippines | Seed, Series A | Health Care, Manufacturing, Biotechnology | $708k–$36M |
|
Yuuwa Capital
VC Fund
|
3 | Australia | Series A, Seed, Series B | Biotechnology, Software, Analytics | $131k–$6.4M |
|
QIC BioVentures
VC Fund
|
3 | Australia | Series A | Medical, Health Care, Biotechnology | |
|
Grok Ventures
VC Fund
|
3 | Australia, United States, Singapore | Series A, Seed, Series B | Renewable Energy, Software, Biotechnology | $808k–$150M |
|
Starfish Ventures
VC Fund
|
3 | United States, Australia, Philippines | Series A, Series B | Software, Enterprise Software, Internet | $2M–$18M |
|
Possible Ventures
VC Fund
|
3 | Germany, Australia, United States | Seed, Pre-Seed, Series A | Software, Biotechnology, Information Technology | $549k–$44M |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Mike Wallas
Angel
|
2 | Australia | Seed | Video, Water, Biotechnology | |
|
Queensland Investment Corporation
VC Fund
|
2 | Australia, United States | Seed, Series A, Series B | Information Technology, FinTech, Software | $673k–$10M |
|
UniQuest
VC Fund
|
2 | United Kingdom | Series B | Medical, Biotechnology | |
|
The George Institute for Global Health
VC Fund
|
2 | Australia | Seed | Biometrics, Health Care, Biotechnology | |
|
Australian Medical Angels
VC Fund
|
2 | Australia, Hong Kong | Seed, Pre-Seed, Series A | Health Care, Machine Learning, Sports | |
|
Tin Alley Ventures
VC Fund
|
2 | Australia | Pre-Seed | Medical, Health Care, Therapeutics | |
|
Tenacious Ventures
VC Fund
|
2 | Australia, United States | Seed, Series A, Pre-Seed | Agriculture, AgTech, Farming | $942k–$49M |
|
Global Health Investment Fund (GHIF)
VC Fund
|
2 | United States, India, Austria | Series B, Series C | Health Care, Biotechnology, Medical Device | $4.5M–$18M |
|
Empath Ventures
VC Fund
|
2 | United States, United Kingdom, Canada | Seed, Pre-Seed, Convertible Note | Health Care, Biotechnology, Personal Health | $100k–$12M |
|
IP Group
VC Fund
|
2 | United Kingdom, United States, Australia | Seed, Series A | Health Care, Biotechnology, Therapeutics | $393k–$23M |
|
Hitachi Ventures
VC Fund
|
2 | United States, Australia, United Kingdom | Series A, Series B, Series C | Software, Artificial Intelligence, Information Technology | $10M–$200M |
|
Vectr
VC Fund
|
2 | United States, Hong Kong, Singapore | Seed, Series A, Series B | FinTech, Financial Services, Artificial Intelligence | $547k–$70M |
|
Investible
VC Fund
|
2 | Australia, United States, Singapore | Seed, Series A, Pre-Seed | Software, Information Technology, FinTech | $221k–$20M |
|
Lowercarbon Capital
VC Fund
|
2 | United States, United Kingdom, France | Seed, Series A, Series B | Renewable Energy, Energy, Biotechnology | $3M–$150M |
|
Closed Loop Partners
VC Fund
|
2 | United States, United Kingdom, Chile | Seed, Series A | Recycling, Manufacturing, Artificial Intelligence | $2.4M–$16M |
|
BridgeLane Capital
VC Fund
|
2 | Australia, Germany, United States | Seed, Series A | Software, Real Estate, Financial Services | $673k–$6M |
|
Folklore Ventures
VC Fund
|
2 | Australia, United States, New Zealand | Seed, Series A | Software, Information Technology, Apps | $500k–$21M |
|
Allan Moss
Angel
|
2 | Australia, United States, The Netherlands | Series A, Seed | Health Care, Medical Device, Biotechnology | $2.4M–$8.8M |
|
Circulate Capital
VC Fund
|
1 | United States, India, Indonesia | Seed, Series B | Recycling, Biotechnology, Manufacturing | |
|
Thistledown Foundation
VC Fund
|
1 | Canada, Australia | Series A | CleanTech, Construction, Biotechnology | |
|
Loyal VC
VC Fund
|
1 | United States, Canada, United Kingdom | Pre-Seed, Seed | Artificial Intelligence, Software, E-Commerce | |
|
Northpond Ventures
VC Fund
|
1 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Life Science | $10M–$100M |
|
Mercia Fund Managers
VC Fund
|
1 | United Kingdom, United States, Hungary | Seed, Series A | Software, Health Care, Biotechnology | $196k–$14M |
|
Acequia Capital (AceCap)
VC Fund
|
1 | United States, United Kingdom, France | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Information Technology | $620k–$25M |
|
AbbVie Biotech Ventures
VC Fund
|
1 | United States, China, Italy | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $6M–$115M |
|
Lilly Ventures
VC Fund
|
1 | United States, Israel, Australia | Series C, Series B, Series A | Biotechnology, Health Care, Therapeutics | $6M–$65M |
|
Alta Partners
VC Fund
|
1 | United States, United Kingdom, China | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $6M–$109M |
|
Catherine Lacavera
Angel
|
1 | Canada, Australia | Seed, Pre-Seed | Medical, Health Care, Biotechnology | |
| Access all 232 investors in Australia Biotechnology startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 80
- Round size: Seed $600k–$4.2M; Series A $1.6M–$16M; Series B $404k–$22M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- DeteQt — Semiconductor chip-based quantum magnetic field sensors using diamond - navigation, mining, medical imaging
- Plasmaleap —
- Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 57
- Round size: Seed $381k–$4.2M; Series A $1.3M–$16M
- Lead/follow: 12% lead, 88% follow
- Last fund: May invest from a new fund soon — raised $14M in 2017
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Morse Micro is a fast-growing wireless integrated circuit solutions company that is reinventing Wi-Fi for the Internet of Things (IoT). The company was founded by Wi-Fi pioneers and innovators, Michael De Nil and Andrew Terry, joined by the original Wi-Fi inventor Prof. Neil Weste and wireless industry veterans, whose teams designed Wi-Fi chipsinto billions of smartphones. Headquartered in Australia with offices in China and the U.S., Morse Micro’s strong and diverse system team, portfolio of IP and patents, enables Wi-Fi HaLow connectivity across the complete IoT ecosystem, from surveillance systems and access control to industrial automation and mobile devices, allowing connected devices to reach farther. www.morsemicro.com
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United Kingdom, United States
Investor stats
- Total investments: 49
- Round size: Seed $673k–$6.7M; Series A $4.9M–$81M; Series B $5M–$120M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $210M in 2019
Portfolio highlights
- CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
- AdvanCell — AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company developing an innovative pipeline of targeted alpha therapies.
- NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 25
- Round size: Series A $1.3M–$13M; Series B $6.4M–$16M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Glyscend Therapeutics — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Manufacturing
- Stage:Seed, Series A, Series B
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 121
- Round size: Seed $1M–$7.1M; Series A $4.5M–$29M; Series B $13M–$73M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $303M in 2023
Portfolio highlights
- Xefco — Xefco is a company that develops novel textile and coating technologies. It uses a global network of research partners to develop advanced manufacturing solutions and apply cutting-edge materials science, with an emphasis on functional enhancements, sustainable manufacturing, and decreased resource consumption.
- ElectraLith — The cleanest, most versatile and most cost-efficient method of extracting and refining lithium, the primary element of a sustainable future.
- Quantum Brilliance — Quantum Brilliance builds diamond-based quantum chips and products that operate at room temperature, enabling mass-deployable quantum technology from data centers to the field.
Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 23
- Round size: Seed $600k–$4.2M; Series A $7.6M–$16M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture.
- Lenexa Medical — Lenexa Medical is an Australian based MedTech company.
- Kinoxis Therapeutics — Developing novel therapeutics for social dysfunction and substance use disorders.
Melbourne Angels was formed in Melbourne, Australia in early 2007. Melbourne Angels is the leading group of private investors in Victoria who actively invest in early stage and growth technology companies.The group has a strong and experienced core of members that generate deal flow, are experienced in evaluation of business propositions and actas mentors for the other members and the entrepreneurs. The members vary in age, gender, ethnicity, profession and type of experience. All members have experience of success at being entrepreneurial.This award winning group is consistently one of the most active startup investors in the country.
Show more...Investment focus
- Industry: Biotechnology, Information Technology, Internet
- Stage:Angel, Seed
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 40
- Round size: Seed $34k–$1.3M; Angel $219k–$918k
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Insite AI — The chosen partner by executives in RGM, insights, and I.T. to grow revenue and market share. Learn how CPGs win in pricing, assortment, trade and more.
- Seitec — Seitec is a security company that manufactures seismic security applications and instruments for civilian and military markets.
- Auric Essentials — Auric - The Power of Scent. Revolutionise your well-being with Auric. Discover our state-of-the-art AI-powered AromaSphere diffuser and app, designed to personalise your aromatherapy experience.
Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 223
- Round size: Seed $120k–$4M; Pre-Seed $40k–$1.5M; Series A $2.3M–$15M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- CUZIN — Providing a surprisingly human shopping experience. Trusted and secure. Millions of domains to choose from.
- Living Models — Living Models is concentrating on this field by employing AI methods on biological data, especially in plant science, where enhancing crop yield and resilience is becoming crucial as global agriculture is impacted by climatic challenges.
- Infiction labs — SPARC 1.2 is a solar panel robotic cleaning system designed and developed by Infiction Labs Pvt Ltd for commercial solar plants.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more...Investment focus
- Industry: Biotechnology, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 250
- Round size: Seed $1M–$11M; Series A $6.2M–$50M; Series B $8M–$110M
- Lead/follow: 44% lead, 56% follow
Portfolio highlights
- Scopely — Scopely is a global interactive entertainment and mobile-first games company, home to many top-grossing, award-winning franchises including “Star Trek™ Fleet Command,” “MARVEL Strike Force,” “Scrabble® GO,” “WWE Champions” and “Yahtzee® With Buddies,” among others. Scopely creates, publishes and live-operates immersive games that empower adirected-by-consumer™ experience. Founded in 2011, Scopely is fueled by a world-class team and a proprietary technology platform Playgami that supports one of the most diversified portfolios in the mobile games industry. Recognized multiple times as one of Fast Company’s “World’s Most Innovative Companies,” Scopely is a multi-billion-dollar business due to its ability to create long-lasting game experiences that players enjoy for years. Scopely has global operations across 17 markets (Asia-Pacific - Bangalore, Seoul, Shanghai, Singapore, Tokyo; EMEA - Barcelona, Dublin, Helsinki, Kyiv, London, Seville, Tel Aviv; North America - Boston, Boulder, Culver City, Mountain View, San Francisco), with additional game studio partners across four continents. For more information, visit www.scopely.com.
- Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
- Amper Music — Amper is an AI music composition company that develops tools for content creators of all kinds. Learn about our new enterprise platform, Score, as well as our creator API.
OneVentures is a later-stage venture capital firm focused on scaling Technology and Healthcare companies through growth equity and credit. The firm's role extends far beyond investment, as the firm actively guides companies toward achieving their next critical milestones. By leveraging decades of global experience and operational expertise,OneVentures accelerates growth and helps shape the future of its portfolio companies.A global growth focus drives their investment selection, with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Series A, Debt Financing
- Geography: Australia, United States, Israel
Investor stats
- Total investments: 71
- Round size: Series A $1.5M–$20M; Debt Financing $1M–$6.7M
- Lead/follow: 46% lead, 54% follow
- Last fund: Likely still investing — raised $145M in 2022
Portfolio highlights
- Hometime — At Hometime, we provide Airbnb property management solutions for homeowners and rental management business owners that help them scale and earn more.
- MyPass Global — MyPass Global is award-winning workforce management software. Join 100's of organisations to reduce costs & simplify compliance, resourcing & recruitment.
- AMP — We make life simpler for merchants navigating the exponential growth of eCommerce with our suite of powerful software, global community, and educational resources.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.
Show more...Investment focus
- Industry: Software, SaaS, Health Care
- Stage:Seed, Angel, Series A
- Geography: Australia, United States
Investor stats
- Total investments: 93
- Round size: Seed $120k–$1.3M; Angel $130k–$890k; Series A $250k–$4.8M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Okkular — Okkular is an AI based fashion tech startup.
- iiShield — iiShield aims to improve patient outcomes and surgeon training in transplant surgery by providing effective organ heat protection.
- Mary Technology — Generate detailed chronologies from documents in minutes with Mary Technology. Achieve 90%+ time reduction and ensure 99%+ accuracy. Try for free.
Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.
Show more...Investment focus
- Industry: Software, Biotechnology, Machine Learning
- Stage:Seed, Angel, Pre-Seed
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 45
- Round size: Seed $120k–$1.3M; Angel $337k–$629k; Pre-Seed $200k–$1.3M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Tendl — Write tenders faster with Tendl's AI tool. Keep your data private and secure. Easy installation, no sharing. Boost productivity and streamline your contract opportunities.
- Shopfront — Automate multi-channel selling across eBay, Depop, Grailed & Shopify. AI-powered listings, bulk uploads, inventory sync.
- Auric Essentials — Auric - The Power of Scent. Revolutionise your well-being with Auric. Discover our state-of-the-art AI-powered AromaSphere diffuser and app, designed to personalise your aromatherapy experience.
Ip Group Australia build and support outstanding intellectual property-based companies.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Renewable Energy
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, New Zealand
Investor stats
- Total investments: 14
- Round size: Seed $938k–$2.3M; Pre-Seed $811k–$942k; Series A $3M–$29M
- Lead/follow: 43% lead, 57% follow
Portfolio highlights
- Hysata — Hysata is a developer of hydrogen electrolyzer designed to accelerate the world's shift away from fossil fuels to green hydrogen
- ElectraLith — The cleanest, most versatile and most cost-efficient method of extracting and refining lithium, the primary element of a sustainable future.
- MGA Thermal — MGA Thermal, specialists in thermal energy storage technology. Renewable, high-power, economical, modular, safe and sustainable thermal storage solutions.
The Clean Energy Finance Corporation invests using a commercial approach to overcome market barriers and mobilize investment in renewable energy, energy efficiency, and low emissions technologies. They seek to catalyze and leverage private sector funding for the commercialization and deployment of clean energy technologies necessary for thetransition to a carbon-constrained economy.
Show more...Investment focus
- Industry: Energy, Renewable Energy, Real Estate
- Stage:Debt Financing, Series B
- Geography: Australia, United States, Spain
Investor stats
- Total investments: 114
- Round size: Series B $5M–$71M; Debt Financing $13M–$333M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $62M in 2018
Portfolio highlights
- Relectrify — Unlocking extra lifetime and performance of batteries via advanced battery management (BMS) technology.
- Wattwatchers — Be more energy efficient and maximise your renewable energy to save money, and the environment.
- Renewable Metals — Renewable Metals' unique alkali recycling process recovers critical minerals from old batteries so they can be used again and again.
Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnologyproduct development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Australia, United Kingdom
Investor stats
- Total investments: 39
- Round size: Series A $2.2M–$9M; Series B $8.8M–$35M; Series C $3M–$55M
- Lead/follow: 23% lead, 77% follow
Portfolio highlights
- Moximed — Moximed Inc. is dedicated to improving the standard of care for patients with osteoarthritis, and is investigating therapies to treat a number of affected joints. The lead product, the KineSpring® Knee Implant System, is designed for patients with knee osteoarthritis.
- Elastagen — Elastagen is a clinical stage medical company with an advanced pipeline of products based on the human protein tropoelastin, a pioneering medical biomaterial. Elastin is a critical component of tissues in the human body which require the ability to stretch and recoil, such as the skin, lungs, arteries, elastic ligaments. Elastagen hasdeveloped a synthetic version of the elastin protein which is identical to that naturally present in the human body. Elastagen’s platform technology has potential applications in a number of areas including skin rejuvenation, scar remodelling and tissue repair. Elastagen was founded following the acquisition of intellectual property rights to the elastin technology which was developed by Prof Weiss at the University of Sydney. The Company has since successfully attracted capital from a number of leading Australian and overseas life science venture capital groups. Elastagen’s operations have expanded from its Australian base to include production in Europe and clinical operations in the UK.
- AirXpanders — AirXpanders develop technology enabling tissue expansion after reconstructive surgery with an emphasis on breast reconstruction. It addresses current unmet needs for patients who require tissue expansion after reconstructive surgery with the first emphasis on breast reconstruction. Present methods of tissue expansion utilize saline-filled implantsthat are typically injected on a weekly basis after surgery in order to reach the volume of skin and tissue required for the placement of a permanent breast implant.
The Breakthrough Victoria Fund is a $2 billion investment by the Victorian Government to drive investment in research and innovation.
Show more...Investment focus
- Industry: Health Care, Manufacturing, Biotechnology
- Stage:Seed, Series A
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 45
- Round size: Seed $708k–$7.1M; Series A $1.8M–$36M
- Lead/follow: 62% lead, 38% follow
Portfolio highlights
- DeepDerm — DeepDerm is developing AI-enabled cameras that detect skin cancer without the need for painful biopsies.
- InnovaIVF — InnovaIVF transforms the reproductive technology landscape with innovative solutions.
- Deftbiotech — Deftbiotech is a biotech startup developing peptide-based antifungal treatments for nail and skin infections.
Yuuwa Capital is a $40M early-stage venture capital firm based in Perth, Western Australia. They are actively seeking outstanding investment opportunities where Yuuwa can provide both capital and expertise to help founders, management and early investors to turn good ideas into great companies.
Show more...Investment focus
- Industry: Biotechnology, Software, Analytics
- Stage:Series A, Seed, Series B
- Geography: Australia
Investor stats
- Total investments: 16
- Round size: Seed $131k–$808k; Series A $979k–$4.2M; Series B $2.6M–$6.4M
- Lead/follow: 63% lead, 37% follow
Portfolio highlights
- Nexgen Plants — Healthy plants, healthy people, living planet. Nexgen develop's plants for future generations that will improve the environment and health of future generations.
- Icetana — icetana Motion Intelligence dramatically improves the active monitoring of security surveillance networks, with AI video anomaly detection and video analytics.
- Agworld — Agworld Farm Management software allows you to collect data at all levels and enables you to extract maximum value from this data; optimising profitability. The Agworld ecosystem is utilised by growers, agronomists and service providers on farms across the world.
QIC BioVentures, previously known as Queensland BioCapital Funds, was established by the Queensland Investment Corporation (QIC) in October 2002 as its venture capital arm specialising in biotechnology. Like any other QIC Fund, QBF's purpose is to maximize investment returns for QIC's clients. QBF does not provide grants or other formsof assistance.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A
- Geography: Australia
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Verva Pharmaceuticals — Verva Pharmaceuticals Ltd. (“Verva”) was formed in December, 2007 by consolidation of key diabetes assets, discovery technologies and targets resident in Autogen Research Ltd. (formerly the diabetes-focused subsidiary of ChemGenex Pharmaceuticals) with those of obesity drug development company Adipogen Pharmaceuticals Pty Ltd. The combined productportfolio, technologies and expertise provide a substantial opportunity for rapid clinical progress and growth in high-value markets with a significant unmet medical need.Verva operates in a completely virtual mode, managed by a CEO and Directors with extensive international product development and partnering experience. Verva’s founding research was undertaken at the Metabolic Research Unit of Deakin University in Geelong, Australia; a state-of-the-art facility providing access to key in vitro and in vivo models and capabilities. Verva has subsequently engaged expert scientists, clinicians, technical advisers and contract research organisations worldwide to implement the Company’s research and development strategy.
- Protagonist Therapeutics — Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs.
Backing a better tomorrow
Show more...Investment focus
- Industry: Renewable Energy, Software, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 66
- Round size: Seed $808k–$10M; Series A $3.3M–$63M; Series B $12M–$150M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Spriggy — Spriggy is a mobile app with a linked prepaid card that helps kids learn the concept of digital money.
- Asterix Foods — Asterix Foods is a biotechnology company designed to build protein production using plant-cell culture techniques. The company's platform is developing and growing bioactive proteins for food that are scalable, functional, and complex, enabling users with plant cell-cultured and animal-free proteins.It was founded in 2022 and is located inTel Aviv, Israel.
- August Robotics — August Robotics creates robots to automate "dirty, dangerous and dull" workflows across the B2B economy. The company's first robot, Lionel, automates the dull and labour intensive task of floor-marking for the global exhibition industry. Lionel has been used as a critical part of the trade show setup process by the world'slargest exhibition companies in Europe and USA. August Robotics' second robot, Diego, automates the dirty and dangerous task of disinfecting high-traffic public areas, such as hotels, offices and aged care centers, optimizing hygiene and reducing the risks of infection. The company is also working on a number of other robots, each leveraging August Robotics' industry leading proprietary mobile robotics platform, which enables August Robotics to generate new robots for new cases far more quickly and cheaply than other robotics companies. The physical world is ripe for disruption by robots, and August Robotics is leading the charge to do this in the B2B segment
Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.
Show more...Investment focus
- Industry: Software, Enterprise Software, Internet
- Stage:Series A, Series B
- Geography: United States, Australia, Philippines
Investor stats
- Total investments: 53
- Round size: Series A $2M–$6.6M; Series B $2.5M–$18M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — raised $134M in 2008
Portfolio highlights
- Aktana — Build stronger relationships with HCPs using Aktana's artificial intelligence (AI) platform for life sciences to optimize omnichannel engagement.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,328,201 freelance designers compete to create amazing designs for your business. Start Today!
- Marani — Marani helps maternity providers quickly identify and manage maternal and fetal risk as well as empowering moms to have healthier pregnancies.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Australia, United States
Investor stats
- Total investments: 162
- Round size: Seed $1.6M–$10M; Pre-Seed $549k–$3.8M; Series A $9.5M–$44M
- Lead/follow: 4% lead, 96% follow
Portfolio highlights
- EntryLevel — Learn in an affordable, peer-driven environment over 6 weeks with mentors from top companies across the world such as Atlassian, Wise and more.
- VSPARTICLE — VSPARTICLE develops nanoparticle generators for various applications such as sensors, batteries, catalysis, solar cells, healthcare, additive manufacturing, nano safety, and more. It also enables research and industry to generate new materials at the push of a button.They specialize in nanoparticle production and integration. The technologyspeeds up the developments of customers by producing the desired nanoparticles on location and integrate them directly in the final product. VSPARTICLE was founded in 2014 and is headquartered in Delft, The Netherlands.
- Auriga Space — Next-generation space launch company providing frequent, sustainable and affordable transport to low Earth orbit
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1482
- Lead/follow: no public data
Portfolio highlights
- MixRift — MIXRIFT - game developers specialized in Mixed Reality
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.
Mike Wallas - Advisory Board @ Optifire Pty Ltd
Show more...Investment focus
- Industry: Video, Water, Biotechnology
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- PERKii — PERKii Targeted Release Probiotics are naturally micro-shielded to resist stomach acid up to 10,000x stronger than non micro-shield probiotics. For a targeted release in your gut and a difference you can feel. PERKii Probiotic Drinks are bottled with one billion or more probiotics per serve.
- Clipchamp — Create videos with royalty-free music and stock footage, use video templates, and export in up to 4K video resolution. Get started in-browser or download the Windows app.
Queensland Investment Corporation is an investment company.
Show more...Investment focus
- Industry: Information Technology, FinTech, Software
- Stage:Seed, Series A, Series B
- Geography: Australia, United States
Investor stats
- Total investments: 17
- Round size: Seed $673k–$5.6M; Series A $6.3M–$10M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $17M in 2022
Portfolio highlights
- One Model — OneModel is a talent analytics accelerator for human resources (HR) departments. It enables companies to measure the productivity and efficiency of their workforces.OneModel helps HR departments handle employees, career pathing, recruiting, succession, exits, engagement, surveys, HR effectiveness, payrolls, planning, and others, all in one place.OneModel was launched in November 2014 and is based in Austin, Texas, United States.
- Paypa Plane — Future-focused payment systems that deliver benefits to banks, enterprises and payers. Working with existing systems to elevate legacy payment structures - Paypa Plane is ready to move the payment ecosystem forward.
- Future Maintenance Technologies — Future Maintenance Technologies delivers AI-enabled robotics and digital systems that automate inspection and maintenance of rail and other critical assets. The company develops solutions such as the Automated Rail Infrastructure Inspection System (ARIIS), which captures and analyses infrastructure data to support condition monitoring and defectdetection. Its platforms integrate sensors, machine vision and analytics to reduce manual track walks and improve maintenance planning. Service offerings include asset management consulting, implementation of digital maintenance systems, and support for global automated maintenance programs. Future Maintenance Technologies collaborates with rail operators and infrastructure owners to embed robotics into existing workflows, helping transition from reactive to predictive maintenance strategies.
UniQuest is a university commercializing and technology transfer company.
Show more...Investment focus
- Industry: Medical, Biotechnology
- Stage:Series B
- Geography: United Kingdom
Investor stats
- Total investments: 3
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- PERKii — PERKii Targeted Release Probiotics are naturally micro-shielded to resist stomach acid up to 10,000x stronger than non micro-shield probiotics. For a targeted release in your gut and a difference you can feel. PERKii Probiotic Drinks are bottled with one billion or more probiotics per serve.
- Vicebio — Discover Sanofi's commitment to scientific innovation, our R&D focus areas, product pipeline, and digital approach to transforming the practice of medicine.
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
The George Institute is on a mission to improve the health of millions of people worldwide. Join us in our fight for a healthier world.
Show more...Investment focus
- Industry: Biometrics, Health Care, Biotechnology
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 3
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- CellSync — CellSync is a Biotechnology Research firm that is working to make changes in the Future of Cell Engineering.
- Sineva — Sineva is a medical device manufacturing firm that makes ultrasonography simulators.
- Neogenix Biosciences — NeoGenix Fertility: Selecting sperm for life through microfluidics and AI
Medical Angels is the premier medical and health-specific angel investment syndicate, comprised of over 1,000 clinicians from across Australia.
Show more...Investment focus
- Industry: Health Care, Machine Learning, Sports
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, Hong Kong
Investor stats
- Total investments: 9
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- GXE — At GXE, our mission is to build the all-in-one platform for unlisted assets and funds management. We provide investors, fund managers, and family offices with the tools they need to succeed and enable them to focus on their portfolios and investors whilst GXE takes care of everything else. A licensed financial services company, GXE holdsAustralian Financial Services Licence 460870 issued by the Australian Securities and Investments Commission. GXE welcomes clients across sectors including corporate, family offices, pension and superannuation fund managers, private equity, property, and venture capital.
- Clean Slate Clinic — Clean Slate Clinic is a telehealth company that provides alcohol detox program who are struggling with alcohol.
- Neogenix Biosciences — NeoGenix Fertility: Selecting sperm for life through microfluidics and AI
Tin Alley Ventures collaborates with companies and researchers in the University of Melbourne's ecosystem to invest in & support world-changing businesses.
Show more...Investment focus
- Industry: Medical, Health Care, Therapeutics
- Stage:Pre-Seed
- Geography: Australia
Investor stats
- Total investments: 3
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Cell Bauhaus — Cell Bauhaus uses mathematical and computer modeling to understand, predict, and modify living cell behavior, aiming to expedite sustainable solutions to humanity's pressing issues.
- Remagine Labs — Remagine Labs is revolutionizing healthcare with a bluetooth-connected, wearable electro-pharmaceutical that provide patient-centered care and consistent drug administration, giving healthcare customers peace of mind all over the world.
- Psychae Therapeutics — Psychae Therapeutics develop innovative pharmaceutical grade DMT-based medicines and therapies aiming to transform the lives of those facing some of the most prolific and insidious mental illnesses
Tenacious Ventures - Australia's first and only dedicated agrifood tech VC firm.
Show more...Investment focus
- Industry: Agriculture, AgTech, Farming
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States
Investor stats
- Total investments: 22
- Round size: Seed $992k–$7M; Pre-Seed $942k–$2.2M; Series A $3.6M–$49M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- Geora — Geora is an open platform for securing and sharing data across agricultural industries.
- RapidAIM — RapidAIM is addressing the lack of information of pest threats to food crops. The company’s platform technology of low-power novel sensors plus edge computing offers a service to the agriculture industry of regional pest surveillance, crop border security, and pest forecasts.
- SwarmFarm Robotics — Global crop protection specialists ADAMA and Australian ag-tech company.
The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series B, Series C
- Geography: United States, India, Austria
Investor stats
- Total investments: 18
- Round size: Series B $7.5M–$18M; Series C $4.5M–$14M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — raised $108M in 2012
Portfolio highlights
- Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
- CXL Ophthalmics — CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally.
- Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Empath Ventures is a venture capital firm that mainly invests in psychedelic medicine companies. The firm specializes in the fields of investment financial services, finance, and venture capital. It was founded in 2021 and headquartered in Los Angeles California.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Personal Health
- Stage:Seed, Pre-Seed, Convertible Note
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 17
- Round size: Seed $100k–$12M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Xylo Bio — Psylo is an Australia-based psychedelic biotech business focusing on Psychedelic-inspired medicine to treat mental illness.
- Motif Neurotech — We're building DOT, a miniature brain stimulator designed to restore healthy brain activity in patients with treatment-resistant depression.
- Aperture Therapeutics — Aperture Therapeutics is building an innovative drug discovery platform that embraces the genetic diversity of patients and leverages mechanistic understanding of protective gene variants in the human population.
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Therapeutics
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 188
- Round size: Seed $393k–$7.6M; Series A $2M–$23M
- Lead/follow: 21% lead, 79% follow
- Last fund: May invest from a new fund soon — raised $125M in 2014
Portfolio highlights
- Lumai — Lumai delivers optical compute for the inference era, enabling up to 50x AI performance and 90% less power. Supports billion-parameter LLMs today.
- AudioScenic — THE NEW DIMENSION IN SOUND
- Intrinsic Semiconductor Technologies — Exciting new developments around the Internet of Things, Big Data, autonomous vehicles, and Artificial Intelligence highlight how our approach to computation must fundamentally change.
Official website of Hitachi, Ltd. Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Series B, Series C
- Geography: United States, Australia, United Kingdom
Investor stats
- Total investments: 56
- Round size: Series A $10M–$50M; Series B $20M–$100M; Series C $30M–$200M
- Lead/follow: 20% lead, 80% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Archetype AI — The Physical AI company helping huminaty make sense of the world.
- Graphon — Graphon is a company that creates relational representation layers and pre-model intelligence for enterprise AI.
- Infravision — Infravision is revolutionizing how the world builds and maintains power grids with our proprietary aerial robotics system.
Vectr is a venture firm based in Hong Kong. They combine investment, creation and growth to deliver game-changing impact to teams ready to tackle global issues, transform industries and improve the lives of millions.That combines capital, creation and partnership to deliver game-changing impact. We strive to be the ideal partner for founders thatare building transformation products and looking to expand their businesses into asia.
Show more...Investment focus
- Industry: FinTech, Financial Services, Artificial Intelligence
- Stage:Seed, Series A, Series B
- Geography: United States, Hong Kong, Singapore
Investor stats
- Total investments: 74
- Round size: Seed $547k–$5.3M; Series A $1M–$37M; Series B $12M–$70M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Percent — Unlock private credit investments with Percent. Access alternative investments on the platform powering the future of private markets.
- Micro Connect — Micro Connect provides market infrastructure, fintech, and platform development.
- MasterExchange — Trading platform for music rights leveraging emerging technology to create friction free and compliant investment opportunities to everyone.
Investible is an early-stage venture capital firm backing the visionaries advancing humanity through technology in Australia, New Zealand, Southeast Asia and globally.
Show more...Investment focus
- Industry: Software, Information Technology, FinTech
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Singapore
Investor stats
- Total investments: 163
- Round size: Seed $221k–$5.3M; Pre-Seed $404k–$2M; Series A $1.4M–$20M
- Lead/follow: 40% lead, 60% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Stables — Save, spend and earn on the same balance
- Mosaic Solutions — Find the top POS supplier in the Philippines for your business needs. Get reliable, efficient, and affordable point-of-sale solutions today!
- Quantum Brilliance — Quantum Brilliance builds diamond-based quantum chips and products that operate at room temperature, enabling mass-deployable quantum technology from data centers to the field.
Lowercarbon Capital backs kickass companies slashing CO2 emissions, sucking carbon out of the sky, and buying us time to unf**k the planet.
Show more...Investment focus
- Industry: Renewable Energy, Energy, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 180
- Round size: Seed $3M–$11M; Series A $10M–$50M; Series B $21M–$150M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — raised $350M in 2022
Portfolio highlights
- Lasso — Tender Food is a plant-based and cultured meat company in the Greater Boston Area, a hub for biotech research and innovation. It specializes in creating alternative meats with authentic textures.
- Lilac Solutions — Lilac Solutions has developed a new ion exchange technology to address the challenges faced by lithium producers. Lilac's technology cuts capital and operating costs, accelerates project startup, boosts lithium recovery, and unlocks new resources. Their process is modular and can be ramped up quickly through pilot and commercial projects.Lilac is a mining technology company and is building partnerships with brine developers and operators around the world.
- Milvus Advanced — Our Midas-touch alloys replicate the functional properties of platinum-group metals at a fraction of the cost.
We Invest in the Circular Economy, a New Economic Model Focused on a Profitable and Sustainable Future.
Show more...Investment focus
- Industry: Recycling, Manufacturing, Artificial Intelligence
- Stage:Seed, Series A
- Geography: United States, United Kingdom, Chile
Investor stats
- Total investments: 43
- Round size: Seed $2.4M–$6.7M; Series A $6M–$16M
- Lead/follow: 44% lead, 56% follow
- Last fund: Likely still investing — raised $200M in 2022
Portfolio highlights
- MOLG — MOLG develops and provides digital and automation tools to manage services and processes of businesses from the manufacturing industry. It is based in Virginia, USA.
- Recycle Ann Arbor — Recycle Ann Arbor's mission is to develop and operate innovative reuse, recycling, and zero-waste programs.
- Reterra — Save the environment with Reterra Corporation in Houston, TX. We recycle PET plastics into sustainable raw materials. Learn more on our site.
The BridgeLane Group is a privately-owned asset management firm specialising in the agricultural, real estate and innovation sectors. A significant global player in agriculture with a multi-decade record in large scale farming, the Group has a proud history in residential property development, comme
Show more...Investment focus
- Industry: Software, Real Estate, Financial Services
- Stage:Seed, Series A
- Geography: Australia, Germany, United States
Investor stats
- Total investments: 20
- Round size: Seed $673k–$4.2M; Series A $3M–$6M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- MadeComfy — Award-winning Airbnb management service in Australia and New Zealand. MadeComfy is a selected official partner of Airbnb. Find out how we earn you higher returns with short-term rentals.
- Futurerent — Futurerent is a tool that offers solutions to residential property investors for investment capital and cashflow needs.
- Evrima Technologies — Our clinical trial recruitment and management services put participants first. Trusted, timely clinical trial results are a good thing - for everybody.
Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.
Show more...Investment focus
- Industry: Software, Information Technology, Apps
- Stage:Seed, Series A
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 45
- Round size: Seed $725k–$5M; Series A $500k–$21M
- Lead/follow: 49% lead, 51% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- Arkeus — Arkeus is a leader in the fusion of optics and autonomy. Our wide area autonomous optical systems are deployed to conduct Search, Intelligence, Surveillance and Reconnaissance in a range of operating environments.
- Sphere — Live courses led by vetted experts for professionals who want to advance their careers
- Visionary Machines — Superior perception for next-generation autonomy
Allan Moss acts an adviser to Anchorage’s Investment Committee. Currently Principal of Allan Moss Investments, a private investment company, Allan retired from the role of Managing Director and Chief Executive Officer of Macquarie Group in May 2008. He was with Macquarie Group for 31 years and served as CEO from 1993 to his retirement in2008. He was also a non- executive director of CSR Ltd from 1996 to 2001.Allan graduated from Sydney University in Arts with a major in Economics and in Laws with Honours. He is also a graduate of Harvard University with a Masters Degree in Business Administration with High Distinction. Allan has received numerous industry awards and recognitions. He was twice named by Barron’s Magazine as one of the 30 most respected CEOs in the world (2006, 2007). He was appointed an Officer of the Order of Australia in 2005.
Show more...Investment focus
- Industry: Health Care, Medical Device, Biotechnology
- Stage:Series A, Seed
- Geography: Australia, United States, The Netherlands
Investor stats
- Total investments: 9
- Round size: Series A $2.4M–$8.8M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Skykraft — Skykraft is an Australian space services firm that specializes in smallsat constellation design, production, and operation.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Invert Robotics — Invert Robotics develops robotic NDT inspection technologies for the maintenance of industrial equipment in the food and beverage, pharmaceutical, and oil and gas industries. Invert Robotics highly skilled team of engineers have developed a world leading modular inspection platform suitable for use across a range of industries and applications.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Circulate Capital is an impact-focused investment management firm dedicated to financing innovation, companies, and infrastructure that prevent the flow of plastic waste into the world's oceans and advance the circular economy.
Show more...Investment focus
- Industry: Recycling, Biotechnology, Manufacturing
- Stage:Seed, Series B
- Geography: United States, India, Indonesia
Investor stats
- Total investments: 17
- Lead/follow: no public data
Portfolio highlights
- Recykal — Recykal is a digital technology company powering a marketplace, building Saas, cloud based solutions for Waste management, recycling industry. Recykal also provides technology solutions for smart cities, municipal corporations and EPR services to FMCG, electronics companies
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
- Ricron Panel — Manufacturer and supplier of high-quality building materials that are waterproof, rustproof, heat resistant, recyclable, lightweight, and fire retardant. We help businesses source sustainable materials for their operations.
Thistledown Foundation is a private charitable foundation.
Show more...Investment focus
- Industry: CleanTech, Construction, Biotechnology
- Stage:Series A
- Geography: Canada, Australia
Investor stats
- Total investments: 3
- Lead/follow: no public data
Portfolio highlights
- Avnos — Our HDAC solution offers the broadest geographic potential available, enabling our technology to operate in water-scarce environments.
- Loam Bio — Loam has designed farmer-focused carbon projects that support farmers to build stable soil carbon in cropping and mixed farming systems.
- CarbonCure Technologies — CarbonCure Technologies creates, develops, and licenses solutions that consume waste CO2 to make better concrete. It spurs the market shift towards affordable green concrete, by enabling concrete manufacturers to convert waste CO2 into solid minerals, locked away as a solid within concrete during manufacturing. It is a green building technologycompany currently serving concrete product manufacturers in the US and Canada. It offers concrete producers the ability to manufacture green concrete products without compromising on either quality or price.CarbonCure is a retrofit innovation that repurposes CO2 gas from large final emitters as a feedstock in concrete plants. The gas is permanently converted into embedded solid mineral carbonates that yield material, environmental, and production advantages. By enabling concrete manufacturers to consume CO2 into concrete products during manufacturing, the technology differentiates an otherwise traditional commodity concrete product, while achieving superior material performance characteristics. In addition to technology, CarbonCure provides demand-pull marketing and environmental reporting/certification services to reinforce its customers’ exclusive competitive positioning. The technology is licensed at a very low-CAPEX to concrete producers, generating a recurring revenue stream.CarbonCure Technologies was founded in 2007 and is headquartered in Halifax, Nova Scotia.
Loyal runs a global venture fund with quarterly redemptions and a proprietary gate-stage process, reducing investment bias and unlocking greater returns. Partnered with INSEAD, Founder Institute, and 500+ advisors, we are Loyal to the world with 250+ investments in 50+ countries.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, E-Commerce
- Stage:Pre-Seed, Seed
- Geography: United States, Canada, United Kingdom
Investor stats
- Total investments: 145
- Lead/follow: no public data
Portfolio highlights
- WASTETIDE — Wastetide turns these wastes into profit, and your excel sheets into useful data.
- Bagel AI — Bagel AI is a product intelligence platform that automates product management, helping product teams turn data into insights, streamline GTM, and drive growth
- Aisel Health — Aisel Health provides AI that imitates psychiatrists for psychiatric clinics and hospitals to ensure efficient patient access to care.
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Life Science
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 127
- Round size: Series A $12M–$68M; Series B $10M–$100M; Series C $22M–$85M
- Lead/follow: 61% lead, 39% follow
Portfolio highlights
- QbDVision — QbDVision's digital CMC software for pharma & biotech accelerates drug development by transforming dispersed data & knowledge to process intelligence.
- Culture Biosciences — Culture Biosciences develops automated bio-reactor that helps biotech companies optimize their manufacturing processes and brings products to market faster. The company also builds automated tools for fermentation. It has a digital bio-manufacturing platform to enable scientists to run, monitor, and analyze bio-reactors faster than traditionalapproaches by robotic sample handling and cloud data monitoring and analysis.Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California.
- Octave — Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.
Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Biotechnology
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Hungary
Investor stats
- Total investments: 133
- Round size: Seed $196k–$2M; Series A $2M–$14M
- Lead/follow: 67% lead, 33% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- 4D Medicine —
- Adludio — Adludio is the AI-powered platform that delivers interactive mobile advertising. By using data to design your ad creative, and algorithms to optimize your campaigns, Adludio makes sure you win the battle for brand attention.
- Role Mapper Technologies — Automate and transform how you design and manage job descriptions across your organisation. Hire, retain and grow an inclusive and diverse workforce with AI powered Intelligent Job Design.
We are a leading early-stage investment platform. We are at the center of a global ecosystem that attracts and fuels the technical founders and product teams building the next wave of global businesses.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 226
- Round size: Seed $1.2M–$8M; Pre-Seed $620k–$3.3M; Series A $5M–$25M
- Lead/follow: 7% lead, 93% follow
- Last fund: May invest from a new fund soon — raised $4M in 2019
Portfolio highlights
- Mutable — Mutable Public Edge Cloud delivers a faster, cheaper, greener and more secure internet.
- Harbinger — Founded by veterans of Canoo and Faraday Future, Harbinger is an automotive company that develops EV platforms optimized for medium-duty trucks and delivery vans.
- MovieBot — Building for a spatial computing future.
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, China, Italy
Investor stats
- Total investments: 49
- Round size: Series A $6M–$53M; Series B $12M–$85M; Series C $39M–$115M
- Lead/follow: 16% lead, 84% follow
Portfolio highlights
- Mozart Therapeutics — The company intended to focus on developing novel immune engagers.
- Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
- DISCO Pharmaceuticals — DISCO Pharmaceuticals is a firm that specializes in large-scale surfaceome unlocking of cancer cells.
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under managementand focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series C, Series B, Series A
- Geography: United States, Israel, Australia
Investor stats
- Total investments: 70
- Round size: Series A $8.9M–$35M; Series B $15M–$65M; Series C $6M–$55M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — last raise in 2009
Portfolio highlights
- IpiNovyx Bio — Orange Grove Bio partners with leading research universities to advance preclinical biotech programs in the oncology space. The company leverages its venture capital and drug development expertise to help patients and build biotech ecosystems.
- Evox Therapeutics — Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics. Backed by leading Life Sciences Venture Capital groups and supported by a comprehensive intellectualproperty portfolio, Evox’s mission is to positively impact human health by creating novel exosome-based therapeutics for the treatment of various severe diseases with limited options for patients and their families.Evox has created substantial proprietary technology to modify exosomes using various molecular engineering, drug loading, and targeting strategies to facilitate targeted drug delivery to organs of interest, including the brain and the central nervous system. Exosome-based drugs have the potential to address some of the limitations of protein, antibody and nucleic acid-based therapies by enabling delivery to cells and tissues that are currently out of reach using other drug delivery technologies. Evox is leading the development within this emerging therapeutic space.
- Kymera Therapeutics — Advancing targeted protein degradation to deliver next-generation medicines
Alta Partners is a leading healthcare and life sciences venture capital firm, helping entrepreneurs build high-impact companies since 1996.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, China
Investor stats
- Total investments: 174
- Round size: Series A $6M–$52M; Series B $16M–$93M; Series C $10M–$109M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — raised $275M in 2021
Portfolio highlights
- EGenesis — At eGenesis, we envision a world where transplantation is accessible to all. We develop safe and effective human-compatible organs for transplantation.
- Be Biopharma — Be Bio is developing a proprietary class of engineered B cells as medicines that unleash the potential of cell therapies in applications beyond cytotoxicity.
- Harbor Health — Harbor Health is a multi-specialty clinic group that provides smarter health care using technology. The company co-creates a health path that is dedicated to knowing individuals' health goals with the guidance of specialists when needed. Harbor Health was founded in 2022 and is based in Austin, Texas.
Catherine Lacavera is the Chief Legal Officer of ShipBob. She previously worked at Color Health as a Chief Legal Officer. Catherine Lacavera attended the University of Toronto.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Pre-Seed
- Geography: Canada, Australia
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Skritswap — skritswap has AI technology that enables anyone to understand anything regardless of complexity.
- HealthMatch — HealthMatch is a medical technology company that applies machine learning and artificial intelligence to clinical data to save lives.We aim to dramatically accelerate patient recruitment to clinical trials, and progress life-saving cures onto the market faster than existing practices allow.For clinicians and patients, there is a real struggleto identify and find appropriate trials, particularly where the criteria relating to each trial is inconsistently articulated. HealthMatch encodes qualifying questions relating to each patients condition. The platform matches responses to its trial dataset, and confirms only the correct-match trials for that patient — thereby streamlining the identification of suitable trials and facilitating a patient’s application to those trials.With Ai and software at the core, HealthMatch delivers a radically simple product to match patients with drug trials, backed by an execution approach to data that is deceptively complex to achieve and replicate. In doing so, HealthMatch is dramatically changing an industry that has essentially not moved beyond telephones and excel spreadsheets.
Biotechnology Investor funding in Australia at a glance
Stats across 222 deals from 232 investors.
Access all 232 investors in Australia Biotechnology startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotechnology Investors in Australia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 232 investors investing in Australia Biotechnology startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!